A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration

BACKGROUND: There is a dearth of patient, preference-based cost-effectiveness analyses evaluating genetic testing for neovascular age-related macular degeneration (NVAMD). METHODS: A Value-Based Medicine, 12-year, combined-eye model, cost-utility analysis evaluated genetic testing of Category 3 AMD...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Gary C., Brown, Melissa M., Lieske, Heidi B., Lieske, Philip A., Brown, Kathryn S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088478/
https://www.ncbi.nlm.nih.gov/pubmed/27847612
http://dx.doi.org/10.1186/s40942-015-0016-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088478/
https://www.ncbi.nlm.nih.gov/pubmed/27847612
http://dx.doi.org/10.1186/s40942-015-0016-5

Ejemplares similares